Saturday - May 3, 2025
MONTRÉAL, March 24, 2023 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leading Canadian Healthtech company, announces that it has filed on SEDAR an amendment to its Management Information Circular (the “Information Circular”) dated February 17, 2023.
Additionally, the Corporation announces that all matters submitted to shareholders for approval as set out in detail in the Corporation’s management Information Circular, were approved at its annual general meeting of shareholders (the “Meeting”) held on Thursday, March 23, 2023. At the Meeting, Raymond Chabot Grant Thornton LLP was re-appointed as the auditor of the Corporation and the following members of the board of directors, Martin Legault, Éric Chouinard, Joseph Cianci, Anne Côté, Hubert Marleau, Jean-Robert Pronovost, Pierre-Luc Toupin, Gilles Seguin and Marie-Andrée Lavoie, were elected for the ensuing year. Shareholders also voted in favour of ratifying and approving the continuation of the incentive Stock Option Plan of the Corporation.
In total, 22,126,575 common shares were voted, representing 39.92% of total shares issued and outstanding as at the record date of the Meeting.
About Premier Health
Premier Health is a leading Canadian Healthtech company that provides a comprehensive range of outsourced services solutions for healthcare needs to governments, corporations, and individuals. Premier Health uses its proprietary LiPHe®️ platform to lead the healthcare services sector digital transformation to provide patients with faster, cheaper, and more accessible care services.
For Further Information Please Contact:
Mr. Guy Daoust
Chief Financial Officer
Premier Health of America Inc.
jrpronovost@premierhealth.ca / 1 800 231 9916
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from those implied by such statements. The Corporation assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. These factors and others are more fully discussed in the filings of the Corporation with Canadian securities regulatory authorities available at www.sedar.com.
Last Trade: | C$0.08 |
Daily Volume: | 0 |
Market Cap: | C$4.160M |
February 28, 2025 January 29, 2025 December 10, 2024 November 14, 2024 August 21, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load